抗血小板和抗凝治疗患者内镜下乳头括约肌切开术后出血风险:美国协作网络的倾向匹配分析
基于TriNetX美国协作网络的回顾性倾向匹配队列研究,纳入住院7天内行ERCP的患者,比较抗凝(AC)和抗血小板(APT)治疗者与匹配对照的乳头括约肌切开术后7天内消化道出血风险。AC组调整OR为3.6(95%CI 2.58-5.06),APT组为2.2(95%CI 1.43-3.56);肝素桥接和联用阿司匹林未进一步增加出血风险,术后24小时内恢复AC则增加风险。
要点
- 抗凝和抗血小板治疗均与乳头括约肌切开术后出血风险升高相关,调整OR分别为3.6和2.2。
- 肝素桥接治疗和联用阿司匹林未进一步增加消化道出血风险。
- 术后24小时内恢复抗凝治疗增加出血风险,两队列均未增加输血、ICU监护或全因死亡风险。
核心结论
- 数据库分析显示,接受抗凝和抗血小板治疗的患者与匹配对照相比,乳头括约肌切开术后出血风险更高。
- 作者认为可考虑在这些患者中采用适当的停药期或替代胆道减压方式。
研究设计与样本
- 回顾性美国 propensity 匹配队列研究,分析TriNetX平台美国协作网络截至2022年12月27日的数据。
- 纳入住院7天内接受ERCP且使用抗血小板或抗凝治疗的患者,进行1:1倾向评分匹配。
- 匹配变量包括年龄、体重指数≥30 kg/m2、性别、种族、族裔、糖尿病、尼古丁依赖、慢性肾病的存在与严重程度、肝硬化和血小板减少症。
主要发现
- 共2806例患者(抗凝队列1806例,抗血小板队列1000例)接受ERCP伴乳头括约肌切开术。
- 抗凝队列较匹配对照的调整OR为3.6(95%CI 2.58-5.06),抗血小板队列为2.2(95%CI 1.43-3.56)。
- 肝素桥接治疗和联用阿司匹林未进一步增加消化道出血风险,术后24小时内恢复抗凝则增加风险。
- 两队列均未增加输血、ICU监护或30天内全因死亡风险。
临床怎么用
- 作者认为可考虑在这些患者中采用适当的停药期或替代胆道减压方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: GI bleeding after ERCP is a serious adverse event and most commonly occurs after endoscopic biliary and/or pancreatic sphincterotomy. Although the strength of available evidence for post-sphincterotomy GI bleeding risk is high for therapeutic warfarin and heparin, it remains unknown for antiplatelet agents like clopidogrel and prasugrel. We conducted a retrospective United States-based, propensity-matched cohort study to assess the risk of post-sphincterotomy bleeding in patients receiving anticoagulant (AC) and antiplatelet (APT) therapy. METHODS: We analyzed the U.S. Collaborative Network in the TriNetX platform through December 27, 2022, to include patients receiving APT and AC therapy who underwent ERCP within 7 days of hospitalization. One-to-one propensity score matching was performed. The primary outcome was the incidence of GI bleeding within 7 days of sphincterotomy. Secondary outcomes included need for blood transfusion, intensive care unit care, and all-cause mortality within 30 days of bleeding. RESULTS: Overall, 2806 patients (1806 in the AC cohort and 1000 in the APT cohort) underwent ERCP with sphincterotomy. One-to-one propensity score matching was performed for age, body mass index ≥30 kg/m2, gender, race, ethnicity, diabetes mellitus, nicotine dependence, presence and severity of chronic kidney disease, cirrhosis, and thrombocytopenia between the cohorts. Patients in both cohorts had an increased risk of post-sphincterotomy bleeding compared with matched control subjects (adjusted odds ratios of 3.6 [95% confidence interval, 2.58-5.06] and 2.2 [95% confidence interval, 1.43-3.56], respectively). Although heparin bridging therapy and concurrent use of aspirin did not further increase the risk of GI bleeding, resumption of AC within 24 hours' postprocedure did. Neither cohort of patients was at an increased risk for blood transfusion, intensive care unit care, or all-cause mortality. CONCLUSIONS: Our database analysis shows that patients receiving AC and APT therapy are at a higher risk of post-sphincterotomy bleeding compared with matched control subjects. An appropriate drug cessation period or alternative biliary decompression modalities may be used in these patients.
引用
- Chandan S, Desai A, Dahiya DS, et al. Risk of post-sphincterotomy bleeding with antiplatelet and anticoagulant use: a propensity-matched analysis of the U.S. Collaborative Network. Gastrointest Endosc. 2023. PMID: 36731579. doi:10.1016/j.gie.2023.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。